Table of Content

i. Cancer Panel Market - Strategic Situation Analysis & COVID Update ..........................20 ii. Guide for Executives, Marketing, Sales and Business Development Staff .....................23 iii. Guide for Management Consultants and Investment Advisors ....................................25 1. Introduction and Market Definition ...................................................................................26
1.1 What are Cancer Gene Panels and Profiling? .................................................................... 27 1.2 The Sequencing Revolution ................................................................................................... 30 1.3 Market Definition .................................................................................................................... 32
1.3.1 Revenue Market Size........................................................................................................ 32 1.4 Methodology .......................................................................................................................... 33 1.4.1 Authors .............................................................................................................................. 33 1.4.2 Sources.............................................................................................................................. 34 1.5 A Spending Perspective on Clinical Laboratory Testing ..................................................... 35 1.5.1 An Historical Look at Clinical Testing............................................................................... 35
2. Market Overview ................................................................................................................38
2.1 Players in a Dynamic Market ................................................................................................. 39 2.1.1 Academic Research Lab ................................................................................................ 40 2.1.2 Diagnostic Test Developer............................................................................................... 40 2.1.3 Instrumentation Supplier .................................................................................................. 40 2.1.4 Distributor and Reagent Supplier .................................................................................... 41

 Page | 5
2.1.5 Independent Testing Lab................................................................................................. 41 2.1.6 Public National/regional lab ........................................................................................... 42 2.1.7 Hospital lab ....................................................................................................................... 42 2.1.8 Physician Office Labs ....................................................................................................... 43 2.1.9 Audit Body ........................................................................................................................ 43 2.1.10 Certification Body........................................................................................................... 43
2.2 Oncogenomics....................................................................................................................... 45 2.2.1 Carcinogenesis................................................................................................................. 45 2.2.2 Chromosomes, Genes and Epigenetics......................................................................... 47
2.2.2.1 Chromosomes .......................................................................................................... 47 2.2.2.2 Genes........................................................................................................................ 49 2.2.2.3 Epigenetics ............................................................................................................... 52
2.2.3 Cancer Genes.................................................................................................................. 53 2.2.4 Germline vs Somatic ........................................................................................................ 55 2.2.5 Gene Panels, Single Gene Assays and Multiplexing ..................................................... 56 2.2.6 Genomic Profiling............................................................................................................. 57 2.2.7 The Comprehensive Assay .............................................................................................. 58 2.2.8 Changing Clinical Role .................................................................................................... 58 2.2.9 The Cancer Screening Market Opportunity................................................................... 60
2.3 Cancer Management vs. Diagnosis ..................................................................................... 60 2.3.1 The Role of Risk Assessment ............................................................................................. 61 2.3.2 Diagnosis ........................................................................................................................... 61 2.3.3 Managing ......................................................................................................................... 61 2.3.4 Monitoring......................................................................................................................... 62


 Page | 6
2.4 Phases of Adoption – Looking into The Future ..................................................................... 62 2.5 Structure of Industry Plays a Part ........................................................................................... 63 2.5.1 Hospital Testing Share ...................................................................................................... 63 2.5.2 Economies of Scale.......................................................................................................... 63 2.5.2.1 Hospital vs. Central Lab ........................................................................................... 64 2.5.3 Physician Office Lab’s...................................................................................................... 65 2.5.4 Physician’s and POCT ...................................................................................................... 66
3. Market Trends......................................................................................................................67
3.1 Factors Driving Growth........................................................................................................... 68 3.1.1 Level of Care .................................................................................................................... 68 3.1.2 Companion Dx ................................................................................................................. 69 3.1.3 Immuno-oncology............................................................................................................ 69 3.1.4 Liability............................................................................................................................... 69 3.1.5 Aging Population.............................................................................................................. 69 3.2 Factors Limiting Growth.......................................................................................................... 71 3.2.1 State of knowledge.......................................................................................................... 71 3.2.2 Genetic Blizzard................................................................................................................ 72 3.2.3 Protocol Resistance.......................................................................................................... 72 3.2.4 Regulation and coverage............................................................................................... 72 3.3 Instrumentation and Automation.......................................................................................... 73 3.3.1 Instruments Key to Market Share..................................................................................... 73 3.3.2 Bioinformatics Plays a Role .............................................................................................. 73 3.4 Diagnostic Technology Development.................................................................................. 74 3.4.1 Next Generation Sequencing Fuels a Revolution.......................................................... 75


 Page | 7
3.4.2 Single Cell Genomics Changes the Picture ................................................................... 76 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment..................................................... 77 3.4.4 CGES Testing, A Brave New World .................................................................................. 77 3.4.5 Biochips/Giant magneto resistance based assay......................................................... 78
4. Cancer Panels & Profiles Recent Developments .............................................................79
4.1 Recent Developments – Importance and How to Use This Section................................... 80 4.1.1 Importance of These Developments .............................................................................. 80 4.1.2 How to Use This Section.................................................................................................... 80 Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform ......... 80 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test............................ 82 Metastatic Cancer Markers Identified in Clinical WGS Study................................................... 82 Stitch Bio Bets on CRISPR Tech..................................................................................................... 85 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program.................................................... 90 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx............ 91 Progress, Challenges in Liquid Biopsy Reimbursement.............................................................. 92 Israeli Startup Curesponse Raises $6M ........................................................................................ 96 Invitae, ArcherDX Merge to Advance Precision Oncology Offerings...................................... 97 MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution ....... 97 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program ........................... 98 Germline Results Guides Precision Therapy in Advanced Cancer .......................................... 99 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics................... 104 ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers ...... 104 Labs Reporting Cancer Risk Mutations from Tumor Testing .................................................... 105 Users Begin Integrating Genomics Data for Clinical Decision Support .................................. 113


 Page | 8
Fujitsu Improves Efficiency in Cancer Genomic Medicine ..................................................... 119 Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results ............ 120 Universal Genetic Testing for All Breast Cancer Patients......................................................... 121 Exact Sciences buys Genomic Health...................................................................................... 122 Multi-Gene Liquid Biopsy Breast Cancer Panel........................................................................ 124 Thrive to Develop Earlier Detection of Multiple Cancer Types ............................................... 125 New Gene Panel Identifies High Risk Prostate Cancer ........................................................... 127 Guardant Health Liquid Biopsy Test to be Covered by EviCore............................................. 128 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services ............................ 129 Natera Commercializes Tumor Whole Exome Sequencing from Plasma .............................. 130 Inivata Completes £39.8M Series B Funding Round................................................................. 131 Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance................................... 132 CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials ............................... 133 Biodesix Acquires Integrated Diagnostics ................................................................................ 134 Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx .......................................... 134
5. Profiles of Key Players .......................................................................................................136 Abbott Diagnostics..................................................................................................................... 137 AccuraGen Inc........................................................................................................................... 139 Acuamark Diagnostics............................................................................................................... 140 Admera Health, LLC................................................................................................................... 141 Agena Bioscience, Inc............................................................................................................... 143 Agilent ......................................................................................................................................... 145 Almac Diagnostics ..................................................................................................................... 147 Amoy Diagnostics Co., Ltd. ....................................................................................................... 148


 Page | 9
Anchor Dx ................................................................................................................................... 149 ANGLE plc ................................................................................................................................... 150 ApoCell, Inc. ............................................................................................................................... 152 ArcherDx, Inc. ............................................................................................................................. 153 Asuragen..................................................................................................................................... 154 AVIVA Biosciences ..................................................................................................................... 156 Baylor Miraca Genetics Laboratories ....................................................................................... 157 Beckman Coulter, Inc. ............................................................................................................... 158 Becton, Dickinson and Company............................................................................................. 160 BGI Genomics Co. Ltd ............................................................................................................... 162 Bioarray Genetics ....................................................................................................................... 164 Biocartis ....................................................................................................................................... 165 Biocept, Inc................................................................................................................................. 166 Biodesix Inc. ................................................................................................................................ 167 BioFluidica ................................................................................................................................... 168 bioMérieux Diagnostics.............................................................................................................. 169 Bioneer Corporation................................................................................................................... 171 Bio-Rad Laboratories, Inc........................................................................................................... 173 Bio-Techne .................................................................................................................................. 175 Bioview ........................................................................................................................................ 177 Blueprint Genetics ...................................................................................................................... 179 Bolidics......................................................................................................................................... 180 Boreal Genomics........................................................................................................................ 181 Caris Molecular Diagnostics ...................................................................................................... 182


 Page | 10
CellMax Life................................................................................................................................. 183 Cepheid (now Danaher) ........................................................................................................... 184 Chronix Biomedical .................................................................................................................... 186 Circulogene................................................................................................................................ 187 Clinical Genomics ...................................................................................................................... 188 Cynvenio..................................................................................................................................... 189 Cytolumina Technologies Corp. ............................................................................................... 190 CytoTrack.................................................................................................................................... 191 Datar Cancer Genetics Limited................................................................................................ 192 Diagenode Diagnostics ............................................................................................................. 193 Diagnologix LLC.......................................................................................................................... 194 Enzo Life Sciences, Inc. .............................................................................................................. 195 Epic Sciences.............................................................................................................................. 197 Epigenomics AG......................................................................................................................... 198 Eurofins Scientific ........................................................................................................................ 199 Exosome Diagnostics.................................................................................................................. 202 Exosome Sciences...................................................................................................................... 204 Fluidigm Corp ............................................................................................................................. 205 Fluxion Biosciences ..................................................................................................................... 207 Foundation Medicine................................................................................................................. 208 Freenome.................................................................................................................................... 209 Fulgent Genetics ........................................................................................................................ 210 GeneFirst Ltd. .............................................................................................................................. 211 Genetron Health (Beijing) Co., Ltd............................................................................................ 212


 Page | 11
Genomic Health......................................................................................................................... 213 GILUPI Nanomedizin ................................................................................................................... 215 Grail, Inc. ..................................................................................................................................... 216 Guardant Health ........................................................................................................................ 218 HansaBiomed ............................................................................................................................. 219 HeiScreen.................................................................................................................................... 220 Helomics...................................................................................................................................... 222 Horizon Discovery ....................................................................................................................... 224 iCellate ........................................................................................................................................ 226 Illumina ........................................................................................................................................ 227 Incell Dx....................................................................................................................................... 229 Inivata.......................................................................................................................................... 230 Invitae Corporation.................................................................................................................... 231 Integrated Diagnostics............................................................................................................... 233 Janssen Diagnostics ................................................................................................................... 234 Loxo Oncology ........................................................................................................................... 235 MDNA Life SCIENCES, Inc........................................................................................................... 236 MDx Health ................................................................................................................................. 237 Menarini Silicon Biosystems ........................................................................................................ 239 Millipore Sigma............................................................................................................................ 240 Miltenyi Biotec............................................................................................................................. 241 miR Scientific............................................................................................................................... 242 Molecular MD ............................................................................................................................. 243 Myriad Genetics/Myriad RBM ................................................................................................... 244


 Page | 12
NantHealth, Inc. ......................................................................................................................... 246 Natera ......................................................................................................................................... 248 NeoGenomics ............................................................................................................................ 250 New Oncology ........................................................................................................................... 252 Novogene Bioinformatics Technology Co., Ltd. ...................................................................... 253 Oncocyte.................................................................................................................................... 255 OncoDNA.................................................................................................................................... 256 Oxford Nanopore Technologies................................................................................................ 257 Perkin Elmer ................................................................................................................................. 259 Personal Genome Diagnostics.................................................................................................. 261 PrecisionMed .............................................................................................................................. 262 Promega ..................................................................................................................................... 263 Qiagen Gmbh ............................................................................................................................ 265 Quidel.......................................................................................................................................... 267 Rarecells SAS............................................................................................................................... 269 RareCyte ..................................................................................................................................... 271 Resolution Biosciences, Inc ........................................................................................................ 272 Roche Molecular Diagnostics ................................................................................................... 273 Screencell ................................................................................................................................... 275 Siemens Healthineers ................................................................................................................. 276 simfo GmbH ................................................................................................................................ 278 Singlera Genomics Inc. .............................................................................................................. 279 SRI International .......................................................................................................................... 280 Sysmex Inostics............................................................................................................................ 282


 Page | 13
Tempus Labs, Inc. ....................................................................................................................... 283 Thermo Fisher Scientific Inc. ....................................................................................................... 284 Thrive Earlier Detection .............................................................................................................. 286 Trovagene................................................................................................................................... 287 Volition......................................................................................................................................... 288
6. The Global Market for Cancer Gene Panels and Profiles ............................................289
6.1 Global Market Overview by Country.................................................................................. 290 6.1.1 Table – Global Market by Country................................................................................ 290 6.1.2 Chart - Global Market by Country................................................................................ 291 6.2 Global Market by Cancer Type - Overview ....................................................................... 292 6.2.1 Table – Global Market by Cancer Type ....................................................................... 292 6.2.2 Chart – Global Market by Cancer Type – Base/Final Year Comparison ................... 293 6.2.3 Chart – Global Market by Cancer Type – Base Year .................................................. 294 6.2.4 Chart – Global Market by Cancer Type – Final Year................................................... 295 6.2.5 Chart – Global Market by Cancer Type – Share by Year ........................................... 296 6.2.6 Chart – Global Market by Cancer Type – Segment Growth ...................................... 297 6.3 Global Market Germline & Somatic - Overview ................................................................ 298 6.3.1 Table – Global Market Germline & Somatic ................................................................ 298 6.3.2 Chart – Global Market Germline & Somatic – Base/Final Year Comparison ............ 299 6.3.3 Chart – Global Market Germline & Somatic – Base Year ........................................... 300 6.3.4 Chart – Global Market Germline & Somatic – Final Year............................................ 301 6.3.5 Chart – Global Market Germline & Somatic – Share by Year..................................... 302 6.3.6 Chart – Global Market Germline & Somatic – Segment Growth ............................... 303
7. Global Cancer Gene Panels & Profiles Markets – By Type of Cancer .........................304


 Page | 14
7.1 Comprehensive Panels & Profiles ........................................................................................ 305 7.1.1 Table Comprehensive Testing – by Country................................................................. 305 7.1.2 Chart - Comprehensive Testing Growth....................................................................... 306
7.2 Breast Cancer Gene Testing................................................................................................ 307 7.2.1 Table Breast Cancer Gene Testing – by Country......................................................... 307 7.2.2 Chart - Breast Cancer Testing Growth.......................................................................... 308
7.3 Colorectal Cancer Gene Testing........................................................................................ 310 7.3.1 Table Colorectal Cancer Gene Testing – by Country................................................. 310 7.3.2 Chart - Colorectal Cancer Gene Testing Growth ....................................................... 311
7.4 Gynecological Cancer Gene Testing ................................................................................ 312 7.4.1 Table Gynecological Cancer Gene Testing – by Country ......................................... 312 7.4.2 Chart - Gynecological Cancer Gene Testing Growth................................................ 313
7.5 Blood Cancer Gene Testing ................................................................................................ 314 7.5.1 Table Blood Cancer Gene Testing – by Country ......................................................... 314 7.5.2 Chart - Blood Cancer Gene Testing Growth................................................................ 315
7.6 Prostate Cancer Gene Testing ............................................................................................ 316 7.6.1 Table Prostate Cancer Gene Testing – by Country..................................................... 316 7.6.2 Chart - Prostate Cancer Testing Growth ...................................................................... 317
7.7 Lung Cancer Gene Testing.................................................................................................. 318 7.7.1 Table Lung Cancer Gene Testing – by Country........................................................... 318 7.7.2 Chart - Lung Cancer Gene Testing Growth ................................................................. 319
7.8 Other Cancer Gene Testing ................................................................................................ 320 7.8.1 Table Other Cancer Gene Testing – by Country ......................................................... 320 7.8.2 Chart - Other Cancer Gene Testing Growth................................................................ 321


 Page | 15
8. Global Cancer Gene Testing Markets – Germline and Somatic..................................322
8.1 Global Market Somatic........................................................................................................ 323 8.2.1 Table Somatic – by Country .......................................................................................... 323 7.2.2 Chart - Somatic Testing Growth .................................................................................... 324 7.3 Global Market Germline ...................................................................................................... 325 7.3.1 Table Germline – by Country......................................................................................... 325 7.3.2 Chart - Germline Testing Growth................................................................................... 326
9. Potential Market Opportunity Sizes .................................................................................327
9.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal ............................... 329 9.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer ............ 331 9.3 Potential Market Size - Cancer Diagnosis........................................................................... 333 9.4 Potential Market Size – Therapy Selection .......................................................................... 335
Appendices ..........................................................................................................................337
I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule ..... 337 II. FDA Approved Human Genetic Tests ................................................................................... 387 III. Pharmacogenomic Biomarkers in Drug Labeling ............................................................... 392



Page | 16
Table of Tables
Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion) ............ 37 Table 2 Market Players by Type ..................................................................................................... 39 Table 3 The Base Pairs...................................................................................................................... 50 Table 4 Five Factors Driving Growth............................................................................................... 68 Table 5 Four Factors Limiting Growth ............................................................................................. 71 Table 6 Key Diagnostic Laboratory Technology Trends ............................................................... 74 Table 7 Next Generation Sequencing Technologies – Speed and Cost .................................... 75 Table 8 - Global Cancer Panel Market by Region...................................................................... 290 Table 9 Global Market by Cancer Type ...................................................................................... 292 Table 10 Global Market Germline & Somatic ............................................................................. 298 Table 11 Comprehensive Testing by Country.............................................................................. 305 Table 12 Breast Cancer Gene Testing by Country..................................................................... 307 Table 13 Colorectal Cancer Gene Testing by Country.............................................................. 310 Table 14 Gynecological Cancer Testing by Country ................................................................. 312 Table 15 Blood Cancer Gene Testing by Country ...................................................................... 314 Table 16 Prostate Cancer Gene Testing by Country .................................................................. 316 Table 17 Lung Cancer Gene Testing by Country........................................................................ 318 Table 18 Other Cancer Gene Testing by Country ...................................................................... 320 Table 19 Somatic by Country ...................................................................................................... 323 Table 20 Germline by Country...................................................................................................... 325 Table 21 Potential Screening Market: Lung, Breast & Colorectal .............................................. 329


 Page | 17
Table 22 Potential Screening Market: Prostate, Other & All ....................................................... 331 Table 23 Potential Cancer Diagnosis Market Size ....................................................................... 333 Table 24 Potential Cancer Management Market Size ............................................................... 335 Table 25 2020 Laboratory Fee Schedule ..................................................................................... 337 Table 26 FDA Approved Human Genetic tests ........................................................................... 387 Table 27 Pharmacogenomic Biomarkers .................................................................................... 392



Table of Figures
Figure 1 VistSeq Hereditary Cancer Panel..................................................................................... 29 Figure 2 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million).......................................... 36 Figure 3 The Genomic Progression of Cancer............................................................................... 46 Figure 4 DNA Strands and Chromosomes ..................................................................................... 47 Figure 5 Karyogram of Human Chromosomes.............................................................................. 48 Figure 6 Size of Various Genomes .................................................................................................. 51 Figure 7 Germline vs Somatic Mutations........................................................................................ 55 Figure 8 Comparing Genomic Diagnostic and Traditional Testing ............................................. 59 Figure 9 Percentage of World Population Over 65....................................................................... 70 Figure 10 Base Year Country Global Share ................................................................................. 291 Figure 11 Global Market by Cancer - Base vs. Final Year .......................................................... 293 Figure 12 Cancer Panel Market Base Year.................................................................................. 294 Figure 13 Cancer Panel Market Final Year .................................................................................. 295 Figure 14 Cancer Type Share by Year ......................................................................................... 296 Figure 15 Cancer Type Segment Growth .................................................................................... 297 Figure 16 Germline & Somatic - Base vs. Final Year .................................................................... 299 Figure 17 Germline & Somatic Market Base Year ....................................................................... 300 Figure 18 Germline & Somatic Market Final Year........................................................................ 301 Figure 19 Germline & Somatic Share by Year ............................................................................. 302 Figure 20 Germline & Somatic Segment Growth ........................................................................ 303 Figure 21 Comprehensive Testing Growth................................................................................... 306


 Page | 19
Figure 22 Breast Cancer Testing Growth...................................................................................... 308 Figure 23 Colorectal Cancer Gene Testing Growth ................................................................... 311 Figure 24 Gynecological Cancer Testing Growth ...................................................................... 313 Figure 25 Blood Cancer Gene Testing Growth ........................................................................... 315 Figure 26 Prostate Cancer Gene Testing Growth ....................................................................... 317 Figure 27 Lung Cancer Gene Testing Growth............................................................................. 319 Figure 28 Other Cancer Gene Testing Growth ........................................................................... 321 Figure 29 Somatic Testing Growth ................................................................................................ 324 Figure 30 Germline Testing Growth .............................................................................................. 326

Table of Tables
Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion) ............ 37 Table 2 Market Players by Type ..................................................................................................... 39 Table 3 The Base Pairs...................................................................................................................... 50 Table 4 Five Factors Driving Growth............................................................................................... 68 Table 5 Four Factors Limiting Growth ............................................................................................. 71 Table 6 Key Diagnostic Laboratory Technology Trends ............................................................... 74 Table 7 Next Generation Sequencing Technologies – Speed and Cost .................................... 75 Table 8 - Global Cancer Panel Market by Region...................................................................... 290 Table 9 Global Market by Cancer Type ...................................................................................... 292 Table 10 Global Market Germline & Somatic ............................................................................. 298 Table 11 Comprehensive Testing by Country.............................................................................. 305 Table 12 Breast Cancer Gene Testing by Country..................................................................... 307 Table 13 Colorectal Cancer Gene Testing by Country.............................................................. 310 Table 14 Gynecological Cancer Testing by Country ................................................................. 312 Table 15 Blood Cancer Gene Testing by Country ...................................................................... 314 Table 16 Prostate Cancer Gene Testing by Country .................................................................. 316 Table 17 Lung Cancer Gene Testing by Country........................................................................ 318 Table 18 Other Cancer Gene Testing by Country ...................................................................... 320 Table 19 Somatic by Country ...................................................................................................... 323 Table 20 Germline by Country...................................................................................................... 325 Table 21 Potential Screening Market: Lung, Breast & Colorectal .............................................. 329


 Page | 17
Table 22 Potential Screening Market: Prostate, Other & All ....................................................... 331 Table 23 Potential Cancer Diagnosis Market Size ....................................................................... 333 Table 24 Potential Cancer Management Market Size ............................................................... 335 Table 25 2020 Laboratory Fee Schedule ..................................................................................... 337 Table 26 FDA Approved Human Genetic tests ........................................................................... 387 Table 27 Pharmacogenomic Biomarkers .................................................................................... 392



Table of Figures
Figure 1 VistSeq Hereditary Cancer Panel..................................................................................... 29 Figure 2 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million).......................................... 36 Figure 3 The Genomic Progression of Cancer............................................................................... 46 Figure 4 DNA Strands and Chromosomes ..................................................................................... 47 Figure 5 Karyogram of Human Chromosomes.............................................................................. 48 Figure 6 Size of Various Genomes .................................................................................................. 51 Figure 7 Germline vs Somatic Mutations........................................................................................ 55 Figure 8 Comparing Genomic Diagnostic and Traditional Testing ............................................. 59 Figure 9 Percentage of World Population Over 65....................................................................... 70 Figure 10 Base Year Country Global Share ................................................................................. 291 Figure 11 Global Market by Cancer - Base vs. Final Year .......................................................... 293 Figure 12 Cancer Panel Market Base Year.................................................................................. 294 Figure 13 Cancer Panel Market Final Year .................................................................................. 295 Figure 14 Cancer Type Share by Year ......................................................................................... 296 Figure 15 Cancer Type Segment Growth .................................................................................... 297 Figure 16 Germline & Somatic - Base vs. Final Year .................................................................... 299 Figure 17 Germline & Somatic Market Base Year ....................................................................... 300 Figure 18 Germline & Somatic Market Final Year........................................................................ 301 Figure 19 Germline & Somatic Share by Year ............................................................................. 302 Figure 20 Germline & Somatic Segment Growth ........................................................................ 303 Figure 21 Comprehensive Testing Growth................................................................................... 306


 Page | 19
Figure 22 Breast Cancer Testing Growth...................................................................................... 308 Figure 23 Colorectal Cancer Gene Testing Growth ................................................................... 311 Figure 24 Gynecological Cancer Testing Growth ...................................................................... 313 Figure 25 Blood Cancer Gene Testing Growth ........................................................................... 315 Figure 26 Prostate Cancer Gene Testing Growth ....................................................................... 317 Figure 27 Lung Cancer Gene Testing Growth............................................................................. 319 Figure 28 Other Cancer Gene Testing Growth ........................................................................... 321 Figure 29 Somatic Testing Growth ................................................................................................ 324 Figure 30 Germline Testing Growth .............................................................................................. 326